IACS-52825
CAS No. 2640376-72-1
IACS-52825( —— )
Catalog No. M37232 CAS No. 2640376-72-1
IACS-52825 is a selective and potent dual leucine zipper kinase (DLK) inhibitor that reverses para-mechanical aberrant pain in a CIPN mouse model for the study of neurological disorders.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 459 | In Stock |
|
| 10MG | 657 | In Stock |
|
| 25MG | 1026 | In Stock |
|
| 50MG | 1386 | In Stock |
|
| 100MG | 1832 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameIACS-52825
-
NoteResearch use only, not for human use.
-
Brief DescriptionIACS-52825 is a selective and potent dual leucine zipper kinase (DLK) inhibitor that reverses para-mechanical aberrant pain in a CIPN mouse model for the study of neurological disorders.
-
DescriptionIACS-52825 is a potent and selective DLK inhibitor with Kd of 1.3 nM, useful for the study of chemotherapy-induced peripheral neuropathy.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorDNA Alkylation
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2640376-72-1
-
Formula Weight426.29
-
Molecular FormulaC16H13F7N4O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES[C@@H](C(F)(F)F)(O)C=1N(C23CC(F)(C2)C3)C=C(N1)C=4C=C(OC(F)(F)F)C(N)=NC4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Kang Le, et al. Discovery of IACS-52825, a Potent and Selective DLK Inhibitor for Treatment of Chemotherapy-Induced Peripheral Neuropathy. J Med Chem. 2023 Jul 27;66(14):9954-9971. ?
molnova catalog
related products
-
Tenatumomab
Tenatumomab (ST2146) is a murine anti-tenascin-C monoclonal antibody used in the study of immune system diseases and lymphomas.
-
9H-Carbazole, 3,6-di...
9H-Carbazole, 3,6-diiodo- is a marine derived natural products found in Kyrtuthrix maculans.
-
Theralizumab
Theralizumab (TGN1412) is an anti-CD28-targeting monoclonal antibody that directly stimulates T cells.
Cart
sales@molnova.com